Company Profile

Syneos Health, Inc. is a biopharmaceutical solutions company that utilizes outsourced clinical drug development and commercialization services. The Company operates through two business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development. The Clinical Solutions segment offers individual services including product development, project management, protocol development, investigational site recruitment, and clinical monitoring. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions (public relations, advertising, and medical communications), and consulting services. The Company's customers include small, mid-sized, and large companies in the biopharmaceutical, biotechnology, and medical device industries.

Employees

28,768

Sector

Biotechnology & Medical Research

More about the company

05-28	Syneos Health, Inc. Announces Appointment of Greg Licholai as Chief Medical Officer, Effective June 1, 2026	CI
05-19	Helio Genomics And Syneos Health Enter Commercial Partnership To Accelerate Nationwide Adoption Of HelioLiver	CI
05-14	Syneos Health Expands Strategic AI Partnerships	CI
05-07	CausaLens and Syneos Health Expand Strategic Partnership to Scale Agentic AI in Biopharma Commercialization	CI
04-30	Kai Conversations and Syneos Health Form Strategic Partnership to Advance U.S. Pharmaceutical Commercialization	CI
03-20	Syneos Health, Inc. acquired Shanghai Bestudy Medical Technology Co., Ltd.	CI
03-20	Big Bidders Reportedly Line Up for Nucleus Network	CI
01-09	Syneos Health, Inc. Appoints Simon Bartle as Chief Human Resources Officer, Effective January 8, 2026	CI
21/10/25	Caremetx and Syneos Health Unite to Accelerate Patient Access	CI
09/10/24	Syneos Health Announces Chief Executive Officer Changes	CI
09/10/24	Syneos Health, Inc. Announces Board Appointments	CI
04/10/24	CytoDyn Inc. Engages Syneos Health as CRO for Its Phase II Oncology Trial	CI
03/10/23	Syneos Health Names Colin Shannon CEO	MT

16/05/23	Mizuho Securities Adjusts Syneos Health Price Target to $43 From $38, Maintains Neutral Rating	MT
11/05/23	Evercore ISI Raises Syneos Health's Price Target to $43 From $38, In Line Rating Kept	MT
11/05/23	JPMorgan Upgrades Syneos Health to Neutral From Underweight, Raises Price Target to $43 From $28	MT
11/05/23	Jefferies Raises Syneos Health's Price Target to $43 From $38, Hold Rating Kept	MT
11/05/23	Morningstar Downgrades Syneos Health to Hold From Buy, Cuts Price Target to $43 From $55	MT

08/07/24	Syneos Health : Releases 2023 Environmental, Social and Governance Report	PU
10/01/24	Syneos Health Releases 2024 Dealmakers Intentions Survey	AQ
18/12/23	Syneos Health : Signs Agreement with University of the Sunshine Coast to Support Clinical Trials in Australia	PU
04/11/23	Syneos Health : Signs Agreement with P3 Research Ltd Network to Support Clinical Trials in New Zealand	PU
02/11/23	Syneos Health : Signs Agreement with GoBroad Healthcare Group to Support Clinical Trials in China	PU

10/05/23	MÄRKTE USA/Uneinheitlich - Preisdaten überzeugen nicht in allen Punkten
10/05/23	MÄRKTE USA/Uneinheitlich - Inflationsdaten überzeugen nicht ganz
10/05/23	MÄRKTE USA/Wall Street mit nachlassendem Preisdruck uneinheitlich
10/05/23	MÄRKTE USA/Wall Street mit nachlassendem Preisdruck im Plus erwartet
10/05/23	En Direct des Marchés : Crédit Agricole, Alstom, Airbus, Casino, Airbnb, Software AG, Ahold, Alcon...

Manager	Title	Age	Since
Costa Panagos CEO	Chief Executive Officer	52	01/10/2024
Michael Bonello DFI	Director of Finance/CFO	57	01/07/2023
Michael Brooks COO	Chief Operating Officer	52	29/04/2022

Syneos Health, Inc. Stock

Stocks

SYNH

US87166B1026

Biotechnology & Medical Research

Latest news : Syneos Health, Inc.

Analysts' recommendations: Syneos Health, Inc.

Press Releases: Syneos Health, Inc.

News in other languages: Syneos Health, Inc.

Quotes and Performance

Managers and Directors: Syneos Health, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Director	Title	Age	Since
James Momtazee BRD	Director/Board Member	54	28/09/2023
Colin Shannon CHM	Chairman	67	09/10/2024
James Dimitri BRD	Director/Board Member	-	28/09/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
28/09/23	Bernadette Connaughton	Issuer sale	Director	14,778	0.0142%
28/09/23	Michelle Keefe	Issuer sale	Director	193,442	0.1865%
28/09/23	Ken Meyers	Issuer sale	Director	25,010	0.0241%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SYNEOS HEALTH, INC.	+0.02%	+0.49%	-	-	4.46B
LONZA GROUP AG	-1.03%	+5.24%	+2.94%	+9.41%	49.74B
REVOLUTION MEDICINES, INC.	+0.25%	+1.70%	+419.39%	+621.71%	40.49B
BEONE MEDICINES AG	-0.16%	+8.42%	+28.20%	+63.00%	34.35B
IQVIA HOLDINGS INC.	+1.10%	+7.77%	+28.18%	-3.96%	34.75B
CELLTRION, INC.	+1.31%	-0.56%	+5.12%	+33.90%	26.98B
ASCENDIS PHARMA A/S	-0.35%	+0.09%	-	-	16.58B
MEDPACE HOLDINGS, INC.	-3.33%	+3.15%	+71.30%	+131.94%	15.6B
IONIS PHARMACEUTICALS, INC.	+3.79%	+8.88%	+106.63%	+106.63%	14.27B
EUROFINS SCIENTIFIC SE	+0.32%	+0.53%	+14.33%	+21.47%	13.76B
Average	+0.19%	+4.21%	+84.51%	+123.01%	27.39B
Weighted average by Cap.	+0.11%	+4.59%	+95.87%	+141.15%